Similar articles

• Considering metabolic effects when making breast cancer treatment decisions.

  Ligibel JA. Ligibel JA. Oncology (Williston Park). 2010 Aug;24(9):844-6. Oncology (Williston Park). 2010. PMID: 20923041 No abstract available.
• Bone Mineral Density and FRAX Score May Not Predict Fracture Risk in Patients With Cancer Undergoing Hormone Deprivation Therapies.

  Dalla Volta A, Mazziotti G, Maffezzoni F, Grisanti S, Palumbo C, Pedersini R, Maroldi R, Berruti A. Dalla Volta A, et al. J Clin Oncol. 2020 Oct 10;38(29):3363-3366. doi: 10.1200/JCO.20.00434. Epub 2020 Jun 30. J Clin Oncol. 2020. PMID: 32603244 No abstract available.
• [Treatment effect of breast cancer and prostate cancer on bone].

  Varsavsky M, Guadalix Iglesias S. Varsavsky M, et al. Med Clin (Barc). 2013 Feb 16;140(4):164-8. doi: 10.1016/j.medcli.2012.05.025. Epub 2012 Jul 28. Med Clin (Barc). 2013. PMID: 22841464 Review. Spanish.
• Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy.

  Redig AJ, Munshi HG. Redig AJ, et al. Oncology (Williston Park). 2010 Aug;24(9):839-44. Oncology (Williston Park). 2010. PMID: 20923040 Review.
• [Anti-aromatase acting drugs].

  Diedrich K. Diedrich K. Krankenpfl J. 2005;43(4-6):150-1. Krankenpfl J. 2005. PMID: 16171094 German. No abstract available.